Vegfrs in neoplastic angiogenesis and prospects for therapy of brain tumors

Medicine and Dentistry

• Angiogenesis 100%
• Vasculotropin 100%
• Brain Tumor 100%
• Combination Therapy 100%
• Tumor Progression 75%
• Receptor 50%
• Angiogenesis Inhibitor 50%
• Tumor Cell 50%
• Neoplasm 25%
• Metastatic Carcinoma 25%
• Growth, Development and Aging 25%
• Cell Invasion 25%
• Endothelial Cell 25%
• Glioblastoma 25%
• Cell Proliferation 25%
• Cell Migration 25%
• Cell Survival 25%
• Brain Cancer 25%
• Antiangiogenic Activity 25%
• Antiangiogenic Therapy 25%
• Cancer Therapy 25%
• Adaptation 25%
• Growth 25%
• Blood Vessel Permeability 25%
• Sorafenib 25%
• Endothelial Progenitor Cell 25%
• Sunitinib 25%
• Cediranib 25%
• Cells 25%
• Survival 25%
• Regulatory Mechanism 25%
• Bone Marrow 25%
• Prognosis 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Neoplasm 100%
• Vasculotropin 100%
• Brain Tumor 100%
• Tumor Growth 75%
• Receptor 50%
• Angiogenesis Inhibitor 50%
• Survival 50%
• Metastasis 25%
• Preclinical Study 25%
• Glioblastoma 25%
• Molecular Target 25%
• Prognosis 25%
• Sunitinib 25%
• Sorafenib 25%
• Brain Cancer 25%
• Cediranib 25%
• Ramucirumab 25%
• Cell Proliferation 25%
• Antiangiogenic Therapy 25%

Biochemistry, Genetics and Molecular Biology

• Vascular Endothelial Growth Factor 100%
• Angiogenesis 100%
• Clinical Trial 75%
• Growth 50%
• Cell Survival 25%
• Cell Proliferation 25%
• Cell Migration 25%
• Preclinical Study 25%
• Tumor Progression 25%
• Adaptation 25%
• Cell Invasion 25%
• Growth, Development and Aging 25%
• Blood Vessel Permeability 25%
• Antiangiogenic Activity 25%
• Sorafenib 25%
• Endothelial Progenitor Cell 25%
• Density 25%
• Bone 25%
• Survival 25%
• Regulatory Mechanism 25%
• Sunitinib 25%
• Cediranib 25%